WinSanTor

Developing The First Disease Modifying Drug to Regenerate Peripheral Nerves

Last Funded April 2024

$707,002

raised from 339 investors

Highlights

1
Drug regenerating peripheral nerves (humans) - combating direct cause of peripheral neuropathy
2
Repurposed medication w/ UNPARALLELED safety profile in FINAL phase (PH3) of clinical studies (DPN)
3
UNMET need affecting 100s of millions, ignored/neglected by industry, e.g., few, if any, competitors
4
VALIDATED science rewarded by innovation grants (>$40M) and licensing deal (>$200M + royalty)

Our Team

WinSanTor was not started as a typical company. Similar to the COVID story (infectious diseases), peripheral neuropathy was neglected by industry (and investors). The leading stakeholders gathered and funded the top researchers in DPN to find solutions. We were lucky. They just happened to discover a way to regenerate nerves, thus WST.

Pitch



























Overview